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Abstract 
The burden of hepatitis C infection is considerable among people who inject drugs (PWID), with an 
estimated prevalence of greater than 40%, representing an estimated 5.6 million people who have 
recently injected drugs living with hepatitis C infection. As such, PWID are a priority population for 
enhancing prevention, testing, linkage to care, treatment and follow-up care in order to meet World 
Health Organization (WHO) hepatitis C elimination goals by 2030. There are many barriers to 
enhancing hepatitis C prevention and care among PWID including; poor global coverage of harm 
reduction services, restrictive drug policies and criminalization of drug use, poor access to health 
services, low hepatitis C testing, linkage to care and treatment, restrictions for accessing DAA 
therapy, and the lack of national strategies and government investment to support WHO elimination 
goals. On 5 September 2017, the International Network of Hepatitis in Substance Users (INHSU) held 
a roundtable panel of international experts to discuss remaining challenges and future priorities for 
action from a health systems perspective. The WHO health systems framework comprises six core 
components; service delivery, health workforce, health information systems, medical procurement, 
health systems financing, and leadership and governance. Communication has been proposed as a 
seventh key element which promotes the central role of affected community engagement. This review 
paper presents recommended strategies for eliminating hepatitis C as a major public health threat 
among PWID and outlines future priorities for action within a health systems framework. 
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Introduction 
Hepatitis B and hepatitis C account for approximately 1.34 million deaths globally, surpassing all 
chronic infectious diseases including HIV, malaria and tuberculosis4. It is estimated that 71 million 
people are living with chronic hepatitis C infection5.  The burden of hepatitis C-related morbidity and 
mortality continues to rise4,6. However, broad access to direct-acting antiviral (DAA) hepatitis C 
regimens with cure rates of over 95%7, provides an opportunity to reverse the rising burden of liver 
disease attributable to hepatitis C infection.  
 
The burden of hepatitis C infection is considerable among people who inject drugs (PWID), with an 
estimated prevalence of greater than 40%, representing an estimated 6.1 million people who have 
recently injected drugs living with hepatitis C infection (9% of all infections globally)5,8,9. There is 
also considerable heterogeneity in the burden of hepatitis C infection among people who have 
recently injected drugs (Figure 1), with half of infections from just four countries: the Russian 
Federation, the United States, China, and Brazil9. PWID are a priority population for enhancing 
prevention, testing, linkage to care, treatment and follow-up care. 
 
Key Points:  
• PWID are a priority population in efforts to eliminate hepatitis C globally  
• There are many interventions effective for hepatitis C prevention, linkage to testing, care, 
and treatment in PWID  
• Future efforts to eliminate hepatitis C among PWID requires interventions across the six 
core components of a health systems framework including: service delivery, health 
workforce, health information systems, medical procurement, health systems financing, and 
leadership and governance 
• Communication is a key component of the hepatitis C elimination response, promoting the 
central role of community engagement and ensuring dynamic interaction among the six 
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In 2016, the World Health Organization (WHO) set an ambitious goal to eliminate hepatitis C as a 
major public health threat by 2030. Specific targets include increasing sterile needles/syringes 
distributed from 20 to 200 per person per year for PWID, reducing new hepatitis C infections by 80%, 
and hepatitis C -related deaths by 65%, and increasing hepatitis C diagnoses from <20% to 90%, and 
the number of people receiving hepatitis C treatment from <10% to 80%10,11. 
 
There are many barriers to enhancing hepatitis C prevention, diagnosis, linkage to care and treatment 
to achieve the WHO targets among PWID. Challenges include poor global coverage of harm 
reduction services, restrictive drug policies and criminalization of drug use, poor access to health 
services, low hepatitis C testing, linkage to care and treatment, restrictions for accessing DAA 
therapy, and the lack of national strategies and government investment to support WHO elimination 
goals7,12. 
 
However, recent advances in the simplification of hepatitis C testing, diagnosis and treatment present 
an opportunity to enhance hepatitis C care among PWID. On 5 September 2017, prior to the 6th 
International Symposium on Hepatitis in Substance Users (INHSU 2017), the International Network 
of Hepatitis in Substance Users (INHSU) held a roundtable panel of international experts in drug and 
alcohol, infectious diseases, and hepatology to discuss remaining challenges and future priorities for 
action from a health systems perspective. Concepts and priorities were further developed through 
subsequent consultation. This paper presents recommended actions based on the expert input from the 
roundtable, follow-up consultation and evidence from the literature. It highlights the available 
scientific evidence regarding strategies to enhance hepatitis C prevention, testing, linkage to care, and 
treatment for PWID and outlines future priorities for action within a health systems framework. 
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Interventions to enhance hepatitis C prevention, testing and treatment to achieve hepatitis C 
elimination among people who inject drugs 
Hepatitis C prevention  
In 2015, there were an estimated 1.7 million new hepatitis C infections globally, with 23% 
occurring among people who inject drugs as a result of sharing of non-sterile injecting 
equipment11, highlighting the elevated hepatitis C incidence among PWID in many settings13-
16, particularly in the initial years of injecting14,17. 
 
There is evidence of the effectiveness of combined opioid substitution therapy (OST) and high-
coverage needle and syringe programmes (NSP) on reducing the risk of hepatitis C acquisition in 
PWID14,15. OST is associated with a 50% reduction in hepatitis C acquisition risk, while combined 
OST and NSP are associated with a 74% reduction in hepatitis C transmissions18. NSP are also 
recognized as one of the most cost-effective public health interventions19. NSP and OST also have 
many other social, health and economic benefits beyond hepatitis C prevention, including prevention 
of HIV transmission and reducing death from overdose20-22. 
 
Increasing hepatitis C treatment among PWID also has potential prevention benefits and is cost-
effective23-25. As per international guidelines, given PWID are at a high risk of hepatitis C 
transmission, and hepatitis C treatment resulting in cure eliminates infectiousness which may yield 
transmission reduction benefits, PWID are a high priority for treatment26-29.  
However, mathematical modelling studies suggest that whilst hepatitis C treatment for PWID can lead 
to substantial reductions in hepatitis C prevalence and reduce transmission30-34, prevention benefits are 
greatest when delivered in combination with OST and NSP31,35,36. Similarly, theoretical modelling 
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indicates that whilst harm reduction has likely averted high HCV prevalence in some settings, scale-
up of OST and NSP alone is unlikely to achieve WHO elimination incidence targets31,37. Therefore, a 
combination prevention strategy including hepatitis C treatment as prevention and increased coverage 
of harm reduction interventions is critical for achieving reductions in hepatitis C prevalence/incidence 
among PWID23.  
 
Hepatitis C testing 
Globally, hepatitis C testing and diagnosis remains inadequate, both in terms of numbers (<20% 
diagnosed) and completeness of tests offered (even fewer have been HCV RNA tested), in particular 
for PWID38-41. In a systematic review of the effectiveness of interventions to improve hepatitis C 
testing among PWID, on-site testing with pre-test discussion and education and dried blood spot 
(DBS) testing were demonstrated to be effective in increasing hepatitis C testing among PWID when 
compared to control interventions42. Other strategies that have been evaluated (without any 
comparator intervention) include physical and electronic medical chart reminders to prompt targeted 
risk-based assessment and testing43-47, peer-delivered outreach hepatitis C testing and hepatitis C 
education48, prison-based outreach testing49, patient referral contact tracing with monetary incentive 
for testing50, and point-of-care hepatitis C testing51-57. Decisions on what intervention(s) to implement 
to enhance hepatitis C testing will depend on the setting (and prevalence of hepatitis C infection), the 
model of care, the local context, and healthcare system. Decisions should also be based on 
engagement with the affected community to assess what testing interventions are most appropriate. 
Interventions should be implemented in a way that is respectful of individual choice and priorities. 
There is a lack of quality evidence on the most effective testing strategies, as such, strategies should 
be trialed and implemented in a way that is consultative and responsive rather than prescriptive.  
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Linkage to hepatitis C care and treatment 
Linkage of PWID to hepatitis C care and treatment is insufficient internationally38-40. In a systematic 
review of studies to improve linkage to hepatitis C care for PWID in the interferon-era, facilitated 
referral (either a nurse, peer-support worker or patient navigator) for hepatitis C assessment and 
scheduling of specialist appointments was associated with improved linkage to hepatitis C care42. 
Integrated hepatitis C care within drug use and psychiatric services delivered by a multidisciplinary 
team with case management services, with or without non-invasive liver disease assessment, was 
associated with improved hepatitis C treatment uptake42. Other strategies evaluated and shown to 
enhance hepatitis C linkage to care and treatment include dried blood spot testing58, point-of-care 
hepatitis C testing54,55, non-invasive liver disease screening using transient elastography (FibroScan®) 
with facilitated referral to care59-61, integrated hepatitis C care43,62-66, patient navigation programs67,68, 
peer-based support69-81, financial incentive programs82,83, and telemedicine84-87. However, the majority 
of interventions that have been evaluated are specific for the interferon-era. Further research is needed 
to evaluate optimal interventions for linkage to hepatitis C care and treatment with interferon-free 
DAA therapy. Similar to efforts to increase hepatitis C testing, decisions on what intervention(s) to 
implement to enhance hepatitis C linkage to care and treatment will depend on the setting and 
prevalence of hepatitis C infection, the model of care, and the local context and healthcare system 
(which includes who can prescribe therapy and the reimbursement restrictions in place).   
 
Models of hepatitis C care 
There is evidence that different models of care are effective for linkage of PWID to hepatitis C care 
and treatment including in hospital-based specialist clinics, community health centers, drug treatment 
clinics, prisons, NSP, supervised consumption rooms, and primary care88. The common theme from 
this spectrum of hepatitis C care models is that “one size does not fit all”88. Models of care which 
provide on-site hepatitis C care in venues where PWID are already accessing services are important88. 
With the availability of simple DAA therapies, the expansion of hepatitis C care to primary care, 
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prisons, and other non-hospital settings, as well as broadening the types of health care professionals 
providing care, will greatly enhance access to hepatitis C care and treatment for PWID.    
 
Hepatitis C treatment 
DAA therapy has improved the feasibility of hepatitis C treatment among PWID compared to 
interferon-based therapies, given DAA therapies have limited psychiatric side-effects, are simpler 
(oral, once-daily vs. weekly injections), and shorter in duration (8-12 weeks vs. 24-48 weeks). DAA 
therapy is effective among PWID receiving OST89-99, people with a history of injecting drug use82,100-
105, and recent PWID99,106-108, including those with hepatitis C/HIV co-infection93-95,101,104,105,109. There 
is no impact of drug use prior to or during treatment on response to DAA therapy among people 
receiving OST98,99 or people with recent injecting drug use99,108. Concomitant alcohol use also has no 
impact on DAA treatment outcomes110. Hepatitis C reinfection incidence among PWID is 0.0-5.3/100 
person-years111-118, with higher rates among those with ongoing injecting (4.9-6.4/100 person-
year)112,114,115,117. Strategies to enhance hepatitis C prevention, such as access to high-coverage NSP 
and OST (>200 needle-syringes distributed per PWID and >40 OST recipients per 100 PWID) are 
crucial to minimize hepatitis C reinfection risk.  
 
Remaining challenges and key recommendations for action from a health systems perspective to 
achieve hepatitis C elimination among people who inject drugs 
 
Health Systems Building Blocks 
A health system, as defined by WHO is all the organizations, institutions, resources and people whose 
primary purpose is to improve health1,2.  The WHO health systems framework comprises six core 
components, some of which underpin other components, such as leadership/governance and health 
information systems, others are input components to the health system (financing and the health 
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workforce), or reflect the outputs of the health system (medical products and technologies and service 
delivery)1,2. Communication has been proposed as a seventh key element. This promotes the central 
role of communication in the context of affected community engagement and ensures dynamic 
interaction among the six traditional building blocks1,2.   
 
Given the interdependent nature of health system components, barriers to hepatitis C care and 
treatment should be systematically addressed across all elements of the health systems framework to 
support sustainable improvement throughout the care cascade (Figure 2).  
 
Communication and Engagement  
A people-centered approach to the health systems framework promotes health care that is respectful 
of, and responsive to, the preferences, needs and values of affected communities. If communication 
and engagement is established as essential to the health systems framework this component provides a 
central tenet on which health strategies can be structured. As people who are actively involved in their 
own health care tend to have better outcomes119, there is potential to move beyond inefficient and 
inequitable health systems by focusing on patient participation and community-led health 
interventions. 
 
Key actions to enhance hepatitis C care for PWID through communication and patient engagement 
include:   
1) Enhancing health care worker communication through education on stigmatizing 
language/terminology, attitudes, practices and policies; 
2) Providing peer-led hepatitis C, health promotion and health literacy education through drug 
user organisations; 
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3) Facilitating consumer participation in hepatitis service design and delivery; 
4) Facilitating patient engagement in hepatitis C communication strategies; 
5) Ensuring patient representation on national hepatitis C strategy planning 
committees/reference groups. 
 
Service Delivery   
Service delivery is the provision of healthcare to people. All inputs to the health system, for example 
health workforce, medical procurement and health information systems are intended to enhance 
service delivery. WHO categorises good service delivery as possessing the following key 
characteristics: comprehensiveness, accessibility, coverage, continuity, quality, person-centeredness, 
coordination, and accountability and efficiency1. 
 
As previously mentioned, there are many effective models of hepatitis C service delivery shown to 
successfully link PWID to care and treatment, all of which require contextual considerations such as 
individual diversity and culture. The same considerations need to be applied to pro-active testing 
outreach campaigns for those individuals not connected to any healthcare services. 
 
New DAA therapies have simplified on-treatment monitoring and the resulting hepatitis C care 
pathway. This has increased the number of settings where hepatitis C services can be provided and 
has enabled a broader range of practitioners to be involved in prescribing (drug and alcohol 
specialists, general practitioners, pharmacists, nurses, and physician assistants) and supporting people 
through testing and care. This simplification has led to a wide spectrum of models of care that can 
improve hepatitis C service delivery.  
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Key actions to enhance hepatitis C service delivery include: 
1) Establishing and supporting hepatitis C testing methodologies that do not require 
venepuncture (e.g. finger-stick and saliva) to enhance hepatitis C diagnosis, linkage to care, 
and treatment in a variety of settings;  
2) Supporting the concept of task-shifting towards the continued expansion of available 
practitioners who can provide hepatitis C testing, linkage to care and treatment;  
3) Delivering services to PWID in a non-judgmental and non-stigmatizing way. 
 
Health Workforce 
The health workforce is defined as ‘all people engaged in actions whose primary intent is to enhance 
health120. WHO identifies human resources as clinical staff, as well as management and support staff, 
i.e. those who do not deliver services directly but are essential to the performance of health systems1. 
 
Given the ease and lower side-effect profile of DAA therapy, it is possible to increase hepatitis C 
treatment through simplified models of care across a range of settings88.  Integrating hepatitis C care 
into new settings, for example drug and alcohol services, entails service delivery by a broader 
multidisciplinary health workforce not previously involved in hepatitis C management42. 
 
Key actions to enhance hepatitis C care for PWID through strengthening the health workforce 
include: 
1) Addressing health workforce limitations through increased hepatitis C education. Education 
must be contextually and culturally appropriate and provided through flexible, blended 
learning i.e. online and face-face. Education should focus on capacity strengthening within 
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health systems through ‘train the trainer’ models and include a key focus on providing non-
stigmatizing care; 
2) Developing and expanding the peer workforce. Peer-based models of care receive a high level 
of patient acceptability and are an effective way of creating trust between services, healthcare 
providers and patients69,121. Health practitioner definitions should be expanded to include peer 
workers as valued members of the health workforce and peers should be supported through 
appropriate remuneration and professional support/supervision; 
3) Encouraging and driving leadership within the workforce e.g. by reaching out to professional 
groups to create champions in various relevant disciplines. 
 
Health Information Systems 
Health information systems are the foundation of decision-making across the health system. They 
enable decision-makers to identify problems and needs, make evidence-based decisions on health 
policy, and allocate resources optimally122.  
 
Despite epidemiological estimates relating to hepatitis C prevalence and burden of disease within 
PWID, there are still gaps in research and monitoring data. Addressing evidence gaps and improving 
methods for data collection is a priority for meeting global hepatitis C elimination goals12.  
 
Key actions to enhance hepatitis C care for PWID through health information systems include: 
1) Developing systems to enable electronic health medical record alerts to enhance hepatitis C 
testing in people at-risk who have not previously been tested or require ongoing risk-based 
testing; 
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2) Assisting clients to understand how their data will be used and how their privacy will be 
protected; 
3) Collecting minimum program information at the outset of hepatitis C treatment scale-up that 
can monitor the uptake of hepatitis C case-finding among PWID, including the number and 
proportion that enter hepatitis C treatment programs; 
4) Creating a hepatitis C treatment registry with linkage between laboratories and community 
hepatitis C treatment providers; 
5) Developing more efficient/flexible digital means of capturing data on hepatitis C testing and 
treatment among PWID (particularly in settings where no registry exists or can be 
established); 
6) Evaluating the impact of DAA treatment on hepatitis C-related morbidity and mortality, 
including hepatitis C prevalence and incidence, incidence of liver cancer and advanced liver 
disease (e.g. decompensated cirrhosis), and death among PWID. 
 
It is noted that as less restrictive care pathways are enabled through point-of-care testing and 
treatment access in community settings, it may become more challenging to establish or maintain 
classical disease registries. This reinforces the need to create alternative, digital means of capturing 
data. 
 
Medical Procurement  
According to WHO, a well-functioning health system ensures equitable access to essential medical 
products and technologies of assured quality, safety, efficacy and cost-effectiveness123.  
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The availability of new hepatitis C diagnostics that are highly sensitive, quick and inexpensive, has 
facilitated the simplification of hepatitis C testing124-129. DAA therapies have also dramatically 
simplified on-treatment monitoring needs124. 
 
Point-of-care and DBS testing have been shown to increase uptake of hepatitis C testing42,47,54-56,130 
and linkage to hepatitis C care54,55,58. Both have the potential to reduce non-attendance to off-site 
phlebotomy and provide more immediate results to facilitate enhanced education and linkage to care. 
This is particularly useful for remote/rural and outreach settings. 
 
Point-of-care hepatitis C testing can include oral fluid rapid diagnostic testing125-129, finger-stick 
whole-blood rapid diagnostic testing126-129,131,132, on-site venepuncture-based testing133,134, and finger-
stick capillary whole blood testing57. Although DBS testing is not strictly point-of-care, the ability to 
collect a finger-stick sample at the point-of-care simplifies sample collection, transportation to the 
laboratory, and diagnosis130,135-137.  
 
Key actions to enhance hepatitis C care for PWID through medical procurement include:  
1) Simplifying, and disinvesting from, existing clinical algorithms for testing and treatment, 
ensuring a focus on improvement engagement with PWID; 
2) Increasing certification of currently available diagnostics – particularly those that do not 
require a venous blood draw - e.g. oral tests, finger-stick blood tests – to increase access to 
testing for PWID; 
3) Developing and certifying affordable diagnostics – particularly those that focus on 
community-based testing and reduce phlebotomy – to increase access to testing for PWID. 
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Health Systems Financing  
Health financing is fundamental to the functionality of the health system. It involves both revenue 
generation/collection and purchasing/provision of services. Optimal health care financing allows 
access to needed services through efficient resource utilization.  
 
The high cost of hepatitis C treatment continues to be a topic of concern; however, given economic 
and population prevention benefits, scaling up hepatitis C treatment and care in PWID has been 
shown to be cost-effective despite high drug costs and risk of reinfection23-25.  
 
Globally, there is a lack of transparency in hepatitis c treatment financing mechanisms. Greater clarity 
and sharing of funding mechanisms would allow for a greater coordinated and effective global 
response.  
 
Exploring new funding mechanisms and ensuring the financial sustainability of hepatitis C prevention 
and treatment programs should be an important focus for all health systems. 
 
Key actions for enhancing hepatitis C care through financing include: 
1) Identifying models of hepatitis C elimination success in settings with different economic 
health system structures and epidemic characteristics; 
2) Advocating for transparent sharing of successes in drug procurement and pricing; 
3) Developing investment cases including budgetary impact, epidemic impact (general and 
among PWID), cost-effectiveness and optimal resource allocation strategies ensuring equity. 
 
A
cc
ep
te
d
 A
rt
ic
le
This article is protected by copyright. All rights reserved. 
Leadership and Governance  
Effective health system leadership and governance enables strategic policy frameworks, effective 
service delivery oversight, coalition-building, regulation, attention to system design and 
accountability123. As a cross-cutting component of the health systems framework, leadership and 
governance is an integral part of improving health outcomes. 
 
In the context of eliminating hepatitis C, although “early adopter” countries, and regions / sites within 
countries, many of whom have developed national strategies, action plans and clinical guidelines, are 
showing that rapid scale up of testing and treatment can be achieved through committed political 
leadership11, not all areas have such governance guidelines. To meet elimination targets by 2030 a 
comprehensive and global public health approach is needed.   
 
Key actions for enhancing hepatitis C prevention and care through leadership and governance include: 
1) Encouraging all countries to develop a national strategy with an action plan; 
2) Ensuring engagement of key affected populations, preferably through leadership roles, in the 
development of national strategies and action plans; 
3) Developing treatment guidelines specifically noting that PWID should not be excluded from 
treatment and addressing primary prevention to prevent reinfection; 
4) Ensuring a financial commitment from national and regional/state governments; 
5) Identifying what scale-up of harm reduction interventions are required to support hepatitis C 
treatment as prevention strategy; 
6) Developing mechanisms for monitoring and evaluation to be able to provide data on whether 
progress is being made; 
7) Identifying champions to drive change – from the community, clinicians, public health and 
government. 
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Conclusion  
People who inject drugs, one of the populations most affected by hepatitis C, should be a priority 
population for interventions to prevent and treat the infection. If hepatitis C elimination is to be 
achieved a people-centered health systems approach is required, providing a framework for action in 
which PWID are engaged in all components of their care, from diagnosis to treatment and follow-up 
care. At present, this is seldom the case. This paper presents a series of recommendations, based on 
expert opinion and published evidence, for how to improve care for PWID in each of the WHO six 
health systems buildings blocks. The seventh central component - ensuring adequate communication 
among the different parts of the health system and the PWID population - is put forth as a core 
element of the hepatitis C elimination response. 
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Figure 1. Estimated number of people with recent injecting drug use living with HCV viraemic 
infection, by country. This figure has been reproduced with permission from9. 
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Figure 2. Proposed modified WHO Health Systems Framework for PWID. This figure has been 
modified from_ENREF_3_ENREF_33. 
  
